PTPA and leukemia: In one of the studies, we demonstrated that PP2A reactivation using a SMAP (TRC-382) is variably effective in a large number of cancer cell lines, including leukemia/lymphoma cell lines that exhibited relatively higher sensitivity (IC50 for solid vs. liquid cancers: 20.43 ± 7.45 vs. 14.98 ± 5.99 μM) (Supplemental Table 4) (29).